Laboratorios Richmond S.A.C.I.F.

RICH

ARLRIC300027

Pharmaceuticals

End-of-day quote Buenos Aires S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
876 ^ARS	-0.34%		-0.51%	+25.41%

Mar. 11	Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 10, 2021

Laboratorios Richmond S.A.C.I.F. Announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced net income was ARS 84.882 million compared to ARS 74.611 million a year ago. For the half year, net loss was ARS 25.264 million compared to net income of ARS 44.339 million a year ago.

Latest news about Laboratorios Richmond S.A.C.I.F.

Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 10	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-10	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Laboratorios Richmond C I F : Argentina's Laboratorios Richmond supplies 1st batch of Russian vaccine	21-08-12	RE
Russian Direct Investment Fund and Laboratorios Richmond Delivers the First Batch of over 1 Million Doses of the Sputnik V Vaccine Produced in Argentina to the Country's Ministry of Health	21-08-12	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-10	CI
Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-10	CI
Laboratorios Richmond C I F : Argentine lab strikes deal to produce Russia's Sputnik V vaccine	21-02-26	RE
Laboratorios Expofarma S.A. announced that it has received $1 million in funding from Laboratorios Richmond S.A.C.I.F., Compañía Inversora Latinoamericana S.A.	18-05-29	CI
Laboratorios Richmond S.A.C.I.F. has completed an IPO in the amount of ARS 524 million.	17-12-20	CI
Laboratorios Richmond S.A.C.I.F. has filed an IPO in the amount of ARS 782.365807 million.	17-12-07	CI
Laboratorios Expofarma S.A announced that it has received funding from Laboratorios Richmond S.A.C.I.F.	16-05-17	CI
Laboratorios Richmond Reportedly Acquires Penn Pharmaceuticals	12-03-29	CI
Laboratorios Richmond S.A.C.I.F. acquired the remaining 40% stake in Penn Pharmaceuticals S.A. from Jorge Romani for $11 million.	12-03-20	CI

Chart Laboratorios Richmond S.A.C.I.F.

Duration

Period

More charts

Company Profile

Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LABORATORIOS RICHMOND S.A.C.I.F.	+25.41%	81.24M
ELI LILLY AND COMPANY	+33.07%	704B
NOVO NORDISK A/S	+28.59%	577B
JOHNSON & JOHNSON	-3.75%	348B
MERCK & CO., INC.	+18.35%	327B
ABBVIE INC.	+5.47%	288B
ASTRAZENECA PLC	+14.81%	234B
NOVARTIS AG	+4.93%	198B
ROCHE HOLDING AG	-9.78%	194B
AMGEN INC.	-3.92%	147B